Key Overactive Bladder Treatment Market Players:
- Bayer AG
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Pfizer Inc.
- Allergan plc / AbbVie Inc.
- Teva Pharmaceutical Industries Ltd.
- Medtronic plc
- Endo International plc
- Urovant Sciences
- Sanofi S.A.
- Johnson & Johnson (Janssen)
- Aurobindo Pharma Ltd.
- Dr. Reddy’s Laboratories Ltd.
- Sun Pharmaceutical Industries Ltd.
- Viatris Inc.
- Mylan N.V.
- AbbVie (merged with Allergan)
The global OAB treatment market is highly competitive. Astellas, Pfizer, Allergan, and AbbVie dominate this market via flagship drugs such as Myrbetriq (mirabegron) and Vesicare, generics from Teva, and also neuromodulation devices marketed by Medtronic. In the competitive landscape, the new entrants from Japan, Sumitomo/Urovant with Gemtesa, Hisamitsu with OABLOK patch, and local manufacturers are developing diversified innovations into non-oral routes and device therapies. Indian generics companies such as Aurobindo, Dr. Reddy's Laboratories, and Sun Pharma reinforce the market on affordability and accessibility in emerging regions.
Here is a list of key players operating in the global market:
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of overactive bladder treatment is assessed at USD 4.7 billion.
The global overactive bladder treatment market size was around USD 4.7 billion in 2026 and is likely to expand at a CAGR of more than 5.4%, surpassing USD 7.95 billion revenue by 2036.
The major players in the global market are Bayer AG, Pfizer Inc., Allergan plc / AbbVie Inc., Teva Pharmaceutical Industries Ltd., and others.
In terms of patient age group, adults (≥18 years) are anticipated to dominate with almost 85% of the market share by 2036.
North America is expected to hold the largest 41% share of the overactive bladder treatment market by 2036, attributed to robust government-funded clinical research and advancements in behavioral and neuromodulation therapies.
